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Abstract Liver X receptors (LXRs) are master regulators
of metabolism and have been studied for their pharmaco-
logical potential in vascular and metabolic disease. Besides
their established role in metabolic homeostasis and disease,
there is mounting evidence to suggest that LXRs may exert
direct beneficial effects in the heart. Here, we aim to pro-
vide a conceptual framework to explain the broad mode of
action of LXRs and how LXR signaling may be an
important local and systemic target for the treatment of
heart failure. We discuss the potential role of LXRs in
systemic conditions associated with heart failure, such as
hypertension, diabetes, and renal and vascular disease.
Further, we expound on recent data that implicate a direct
role for LXR activation in the heart, for its impact on
cardiomyocyte damage and loss due to ischemia, and
effects on cardiac hypertrophy, fibrosis, and myocardial
metabolism. Taken together, the accumulating evidence
supports the notion that LXRs may represent a novel
therapeutic target for the treatment of heart failure.
Keywords Cardiac remodeling  Cardiovascular risk
factors  Heart failure  Hypertrophy  Liver X receptors 
Metabolism
Introduction
The prevalence of heart failure is increasing in our aging
society and is associated with significant morbidity and
mortality [88]. It is a complex clinical syndrome and diag-
nosis is based on physical signs and symptoms of dyspnea,
fluid retention, and fatigue upon exertion. Heart failure is
attributed to a process of pathological cardiac remodeling
that is initiated via molecular, cellular, and interstitial
changes that structurally and functionally alter the myo-
cardium [54]. Cardiac remodeling is initially a compensatory
response to injury such as myocardial infarction or hyper-
tension, but is maladaptive when these factors continue
unabated, perpetuating the progression toward cardiac dys-
function and heart failure. The time course and extent of
remodeling are influenced by several factors such as the
severity of the pathological insult, secondary events
including recurrent ischemia or infarction, elevated hemo-
dynamic load, and neurohormonal activation.
Heart failure manifests as a state of impaired pump
function that results in inadequate cardiac output, and
classification is based on left ventricular (LV) ejection
fraction which is either reduced (HFrEF) or preserved
(HFpEF) (Fig. 1) [46]. The dominant cause of HFrEF is
coronary artery disease, and the underlying mechanisms
that drive ventricular remodeling are the result of the
ischemic injury caused by myocardial infarction. In the
infarct zone, a fibrotic scar replaces loss of cardiomy-
ocytes, whereas the remote myocardium undergoes
eccentric remodeling that leads to LV dilatation, decreased
contractility, and impaired systolic function. In contrast,
HFpEF patients demonstrate evidence of diastolic dys-
function, including prolonged LV relaxation time, reduced
LV filling, and increased myocardial stiffness [101], and
often involves concentric remodeling of the myocardium.
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Most pharmacological therapies such as b-blockade and
inhibitors of the renin-angiotensin-aldosterone system
(RAAS) have proven efficacy in HFrEF by reducing mor-
bidity and mortality [14]. However, this strategy has not
been as successful for treating HFpEF [85], therefore
diagnosing and treating HFpEF remains a challenge. In
essence, the underlying pathophysiology of HFpEF is
poorly understood largely owing to the presence of multi-
ple co-morbidities such as hypertension, diabetes, meta-
bolic syndrome, atrial fibrillation, and renal and vascular
disease, which impact the pathogenesis of this syndrome
and contribute to the complexity of mechanisms governing
cardiac remodeling [86]. Lack of a clear understanding of
these mechanisms thus poses several challenges in target-
ing and treating heart failure. Identification of novel
pleiotropic targets that are integrative across multi-organ
systems may therefore be effective therapeutic strategies in
preventing or reversing heart failure.
Liver X receptors (LXR) a and b belong to the nuclear
receptor superfamily of ligand-activated transcription fac-
tors. LXRs have emerged as important regulators of
cholesterol homeostasis, lipid and glucose metabolism, and
inflammation, and so have been regarded as promising
therapeutic targets for intervention in atherosclerotic and
metabolic disease [130]. They were originally discovered
in the mid-1990s as ‘‘orphan receptors’’ because their
natural ligands were yet unknown [4, 120, 137]. Shortly
thereafter, oxysterols as well as cholesterol metabolites
were identified as endogenous activators of LXRs, thus
LXRs were ‘‘deorphanized’’ [60]. In the nucleus, LXRs
form obligate heterodimers with the retinoid X receptor
(RXR) and are bound to LXR response elements (LXREs)
Fig. 1 Impact of systemic LXR signaling on co-morbidities associ-
ated with heart failure pathogenesis. The progression of atheroscle-
rotic vascular disease increases the risk for myocardial infarction.
Myocardial infarction causes eccentric remodeling of the myocar-
dium and loss of systolic function; it is the predominant etiology
underlying heart failure with reduced ejection fraction (HFrEF). The
presence of co-morbidities such as hypertension, atrial fibrillation,
diabetes, metabolic syndrome, renal disease, and aging, all impact the
heart, which results in concentric hypertrophic remodeling and loss of
diastolic function. This ultimately leads to the pathogenesis of heart
failure with preserved ejection fraction (HFpEF). Cardiac remodeling
is initially reversible, however, the prevalence of co-morbidities
further aggravates the progression of both HFrEF and HFpEF such
that adverse remodeling is accelerated and becomes largely irre-
versible. Consequently, death is inevitable. Liver X receptors (LXRs)
are implicated as a protective target in the pathogenesis of heart
failure for their beneficial effects in the development of atheroscle-
rosis, insulin resistance and diabetes, nephropathy, and blood pressure
modulation*
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in regulatory regions of target genes. Binding of either their
natural or synthetic ligands, such as T0901317 (T09) and
GW3965, induces a conformational change in the LXR/
RXR complex that facilitates activation of target gene
transcription (Fig. 2). LXRb is ubiquitously expressed,
whereas LXRa features more abundantly in metabolically
active systems such as the liver, adipose tissue, and mac-
rophages, as well as in heart, skeletal muscle, kidney, and
lung [102]. In the heart, expression levels of both LXRs are
10- to 15-fold higher in the non-myocytic compartment,
consisting of fibroblasts and endothelial cells, compared to
the myocyte compartment [79].
Here, we review recent evidence regarding the systemic
effects of LXRs in relation to co-morbidities that are
relevant in heart failure pathogenesis. Although studies of
LXRs in the heart are few, they have generated clear evi-
dence that LXR signaling exerts a potential cardioprotec-
tive role in cardiac remodeling and myocardial disease.
Altogether, we provide a perspective on the potentiality of
LXRs as an integrative target for the treatment of heart
failure.
Systemic effects of LXR signaling
in the development and progression of heart
failure
Combined co-morbidities have a major impact on the
pathogenesis of heart failure, which led to the supposition
that myocardial dysfunction may not originate exclusively
in the heart itself, but extrinsic factors that stem from these
co-morbidities may perturb the heart [115]. Here, current
knowledge on the role of LXRs in the pathogenesis of
several of these co-morbidities, including atherosclerosis
and vascular disease, hypertension, diabetes, metabolic
syndrome, and chronic kidney disease, is summarized
(Table 1). Given the widespread effects of LXRs, we
postulate that systemic LXR activation may play an
important role in conferring myocardial protection from
these disorders that collectively contribute to the patho-
genesis of HFrEF and HFpEF.
LXR and atherosclerosis
Atherosclerosis contributes to multi-organ dysfunction
involving the kidney, brain, gut, and skeletal muscle, and is
a major cause of HFrEF following myocardial infarction.
LXRs have been extensively studied for their putative
atheroprotective functions [15]. The initial stages of
Fig. 2 Mechanism of liver X receptor activation. In the nucleus,
LXRs form an obligate heterodimer complex with the retinoid X
receptor (RXR) that binds to an LXR response element (LXRE) in
regulatory regions of target genes. Following ligand binding, the
LXR/RXR complex undergoes a conformational change that leads to
the release of co-repressors and the recruitment of co-activators,
which activates target gene transcription
Table 1 Systemic effects of liver X receptor activation in relation to co-morbidities relevant in heart failure pathogenesis
Positive effects of LXR activation
Atherosclerosis Hypertension Diabetes Chronic kidney disease
: Cholesterol efflux [102, 103] : Renin modulation [92, 127] : Glucose tolerance [18, 77] ; Albumin:creatinine ratio [72, 99, 126]
; Lesion development [64, 128] ; AT1R expression [57, 76, 80] : Insulin sensitivity [18] ; Lipid accumulation [72, 99]
; Inflammation [63] : Vasoreactivity [80] ; Endothelial dysfunction [50,
83]
; Inflammation [72, 99, 126]
: Vascular protection [11] [22] ; Blood pressure [75, 80] ; Fibrosis [72]
Negative effects of LXR activation
Lipogenic Central nervous system




: Psychiatric events [69]
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atherosclerosis involve the formation of foam cells by the
uptake of oxidized low-density lipoprotein (LDL) in mac-
rophages in the arterial wall. Mice deficient for both LXRa
and LXRb develop increased foam cell formation, impli-
cating a basal role in cholesterol homeostasis [114]. LXRs
limit pathogenic accumulation of cholesterol in macro-
phages by enhancing the rate of cholesterol efflux [94],
which is mediated through upregulation of genes involved
in all aspects of the reverse cholesterol transport (RCT)
pathway, including Abca1, Abcg1, and ApoE in cellular
cholesterol efflux, CETP and PLTP in plasma lipid trans-
port, Abcg5 and Abcg8 for entero-hepatic sterol absorption
and excretion, and Cyp7a1 for enhanced bile acid excretion
[109]. In murine models, LXR agonist treatment signifi-
cantly reduced atherosclerosis in both Ldlr-/- and apoE-/-
mice [64], whereas selective loss of macrophage LXR
activity through bone marrow transplantations markedly
increased lesion development in these models [128].
Interestingly, liver-specific deletion of LXRa in mice leads
to decreased RCT, cholesterol catabolism, and excretion
while substantially increasing atherosclerosis, altogether
underscoring their importance as whole-body cholesterol
sensors [143].
In macrophages, the metabolic functions of LXRs are
coupled to anti-inflammatory responses, which further
contribute to the mechanism underlying their atheropro-
tective effects. LXR agonist activation inhibits the induc-
tion of pro-inflammatory cytokines through a mechanism
involving transrepression [63]. In atherogenic Ldlr-/-
mice, selectively increasing LXRa in macrophages leads to
reductions in plasma inflammatory cytokines, IL6 and
TNFa, and atherosclerotic lesion development [82].
Moreover, in the absence of cholesterol efflux pathways
mediated by Abca1/g1-deficient macrophages, LXR ago-
nism nonetheless decreased lesion area, complexity, and
inflammatory cell infiltration, including plasma levels of
the chemokine, MCP1 [67]. LXRs have also been shown to
target the inflammatory process in atherogenesis at a crit-
ical step through the inhibition of chemokine-induced
CD4-positive lymphocyte migration [133].
More recent evidence implicates additional atheropro-
tective properties of LXR agonists in the pathogenesis of
atherosclerosis that extend beyond their capacity to pro-
mote peripheral cholesterol efflux and inhibit inflamma-
tion. A novel anti-atherosclerotic mechanism for LXRa
through regulation of macrophage iron homeostasis has
been identified. By increasing iron export, LXRa reduces
iron loading which promotes formation of oxidized lipids,
an inducer of cell death [12]. Other functions for LXRs
within the vasculature are emerging. Endothelial dysfunc-
tion is the underlying cause of all vascular diseases and is a
critical initiator of atherosclerosis. LXRs are expressed in
endothelial cells [121], and their distribution in murine
aortas reveals a greater degree of expression in the
atheroprotective thoracic region than in atheroprone areas
such as the aortic arch, supporting an anti-atherogenic
function [145]. In atherosclerotic vessel walls, studies
indicate that LXR activation decreases vascular expression
of adhesion molecules such as E-selectin, ICAM-1, and
CD44 [131], and improves arterial vasomotor function
through enhanced endothelium-dependent vasorelaxation
[22].
Also of relevance are the reparative effects of LXRs in
vascular injury. The progression of atherosclerosis is
accelerated via denuding of the endothelium and intimal
injury, which are accompanied by platelet deposition,
thrombus formation, and smooth muscle cell proliferation.
In rodent models of carotid artery injury, LXR ligands
repaired damaged vessel walls by advancing endothelial
regeneration through increased proliferation and migration
of endothelial progenitor cells and enhancing their secre-
tion of vascular endothelial growth factor (VEGF) [140], as
well as inhibiting vascular smooth muscle cell proliferation
and neointima formation [11]. Also of note is the identi-
fication of a novel role for LXRs in thrombosis and platelet
function. Although platelets are anuclear, they reportedly
express LXRb and GW3965 treatment has been shown to
inhibit platelet accumulation and thrombi formation [122].
Taken together, evidence of an atheroprotective role for
LXRs continues to broaden as studies reveal novel func-
tions in cholesterol efflux, macrophage activity, and vas-
cular protection. Preventing atherosclerotic lesion
development is of paramount importance in offsetting
coronary syndromes such as myocardial infarction, the
major cause of systolic dysfunction leading to HFrEF.
Thus, LXRs represent a promising target in the etiology
underlying HFrEF and subsequent mortality.
LXR and hypertension
In HFpEF, hypertension is the most prevalent co-morbidity
[89] and precedes heart failure in 60–90 % of all cases
[81]. Besides being a risk factor for atherosclerosis and
causing vascular injury, hypertension affects the cardiac
muscle by invoking pathological hypertrophic growth
through increased hemodynamic afterload.
The RAAS is a predominant hormonal signaling path-
way in the regulation of blood pressure, fluid balance, and
systemic vascular resistance. LXRs have been implicated
in blood pressure control through modulation of the RAAS.
Initial observations identified LXRa as a regulator of renin
transcription [92, 127]. Acute administration of LXR
agonists directly increased renin mRNA levels in vivo,
whereas LXR-null mice lost their capacity to upregulate
renin under b-adrenergic stress [92], suggesting a crosstalk
between LXR signaling and the RAAS. In subsequent
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studies, chronic LXR activation inhibited isoproterenol-
induced components of the RAAS, including renin, but also
angiotensin converting enzyme (ACE) and angiotensin
type I receptor (AT1R) expression in kidneys and heart
[76]. Furthermore, in vivo investigation of the functional
effects of LXRs on RAAS activation revealed that LXR
agonism abolished angiotensin (Ang) II-induced increases
in blood pressure in rats [80]. Although improved vasore-
activity was not unequivocally linked to the level of RAAS
activation, these findings suggest that LXRs decrease
peripheral vascular resistance and potentially lower blood
pressure. In line with this, the LXR agonist T09 was found
to reduce the elevation in blood pressure due to chronic
pressure–volume overload in mice, whereas this effect was
absent in mice lacking LXRa [75].
The RAAS is not only regulated by mechanisms that
stimulate renin release, but is also modulated by natriuretic
peptides, ANP and BNP, which are produced by the heart
and antagonize the RAAS pathway. Recently, overex-
pressing cardiac LXRa has been shown to upregulate
natriuretic peptide expression [16] (Cannon et al., unpub-
lished data); therefore, LXRa modulation of natriuretic
peptides may represent an indirect mechanism for RAAS
suppression. Overall, existing evidence suggests that LXRs
play a role in antagonizing RAAS activation and may be a
viable target in alleviating the hemodynamic burden
imposed on the heart.
LXR and diabetes
Disturbances in energy balance leads to impaired periph-
eral glucose utilization and the development of insulin
resistance and type II diabetes, both of which increase the
risk for cardiovascular disease [58]. Diabetes accelerates
atherosclerosis, but also directly causes myocardial
hypertrophy and diastolic dysfunction in the absence of
hypertension or coronary artery disease [43].
LXR agonists have been recognized as a potential
pharmacological strategy for the treatment of diabetes and
associated metabolic disorders [45]. Multiple studies have
established the importance of LXRs in glucose metabolism
and in the adaptation to metabolic stress that triggers dia-
betes. In rodent models of type II diabetes and insulin
resistance, LXR agonists have been shown to reduce
plasma glucose [18, 84] and improve glucose tolerance and
insulin sensitivity [18, 29, 48, 77, 84]. Mechanisms
underlying the beneficial effects of LXRs on glucose
homeostasis span several organ systems including the liver,
adipose tissue, skeletal muscle, and pancreas. In the liver,
LXR agonists suppress gluconeogenesis by downregulating
Pgc1a, Pepck, and G6Pase genes, and induce glucokinase
to promote hepatic glucose utilization [18, 77, 125]. In
adipose tissue and skeletal muscle, LXRs directly regulate
transcription of the glucose transporter, Glut4, and enhance
peripheral glucose uptake both in the absence [33, 77] and
presence of diabetes [6, 68]. In pancreatic islet cells, an
important homeostatic role for LXRb has been elucidated
as Lxrb-/- mice are intolerant to glucose due to impaired
glucose-stimulated insulin secretion [44], whereas LXR
ligands have been found to promote b-cell insulin secretion
[39, 44, 48].
Although LXR agonists represent promising anti-dia-
betic agents given their insulin-sensitizing effects, the
favorable effects on glucose metabolism need to be dis-
sociated from their lipogenic effects for these compounds
to be of potential clinical use (Table 1). LXR agonists
enhance hepatic and skeletal muscle lipid accumulation
and increase circulating triglycerides [30, 68], which
worsens the lipogenic pathology in diabetes [26]. Chronic
LXR activation may also impair insulin secretion by con-
tributing to lipotoxicity-induced pancreatic b-cell apoptosis
[27]. To circumvent these ramifications, alternative
approaches are being initiated which include the develop-
ment of partial LXR ligands or LXRb-specific agonists
since lipogenesis is mediated primarily via LXRa [59].
Interestingly, a recent study reported that administration of
the LXR agonist T09 in combination with metformin, an
established oral anti-diabetic drug, ameliorated the devel-
opment of hepatic steatosis induced by LXR agonism in
diabetic rats [49], suggesting that combinatorial therapies
may also be viable.
Apart from metabolic dysregulation, diabetes is also
characterized by low-grade inflammation that stems from
macrophage infiltration in adipose tissue and secretion of
pro-inflammatory cytokines [129]. By antagonizing
NFjB signaling in the nucleus, LXRs have been shown
to inhibit the induction of pro-inflammatory genes
encoding iNOS, COX-2, IL6, and MCP1 [63]. To date,
the impact of the anti-inflammatory functions of LXRs
on diabetic pathophysiology is largely unknown. Since
chronic systemic inflammation predisposes toward
myocardial dysfunction and resultant HFpEF [100], we
postulate that LXRs may protect the heart, amongst other
susceptible organs, from diabetes- and obesity-induced
inflammation.
In summary, LXRs are implicated in the protection
against diabetes through modulation of glucose metabo-
lism, b-cell insulin secretion, and inflammatory signaling,
including recent developments indicating vasoprotection
from hyperglycemia-induced endothelial dysfunction [50,
83]. Overall, LXRs mediate several pathways involved in
diabetes, and as such, potentially affect the pathogenesis of
HFpEF. These multiple effects are also linked to other co-
morbidities contributing to heart failure development:
atherosclerosis, the major cause of HFpEF, which is further
aggravated by the presence of diabetes, as well as diabetes-
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induced kidney damage, which results in renal dysfunction,
failure, and eventual HFpEF (discussed below).
LXR, obesity and metabolic syndrome
The metabolic syndrome is comprised of a cluster of
metabolic abnormalities that include disturbances in glu-
cose homeostasis, insulin resistance, obesity, dyslipidemia,
and elevated blood pressure. These conditions increase the
risk of developing cardiovascular disease and diabetes.
Maintaining glucose homeostasis and improving insulin
sensitivity are important effects of LXRs that potentially
influence the development of insulin resistance and dia-
betes. However, the role of LXRs in modulating the
molecular pathogenesis of the metabolic syndrome is less
clear.
LXRs are critically involved in cholesterol homeostasis
and lipid metabolism. In Lxra-/- and Lxra/b-/- mice,
serum LDL is increased and HDL is decreased, but not in
Lxrb-/- mice, whereas serum and VLDL and LDL
triglycerides are reduced in double-mutants [114]. Further,
LXR agonism treatment lowers total and unesterified
cholesterol levels in atherogenic Ldlr-/- mice [64]. In
addition to promoting RCT [94], LXRs have also been
shown to limit LDL receptor-dependent cholesterol uptake
by transcriptionally inducing Idol, an E3 ubiquitin ligase
that triggers ubiquitination of the LDL receptor, targeting it
for degradation [141].
Apart from enhancing cholesterol catabolism and
transport, LXRs are centrally involved in promoting hep-
atic lipogenesis. LXRs induce lipid synthesis by directly
regulating the expression of Srebp1c and downstream tar-
get genes, Acc, Fas, and Scd1 [108]. Furthermore, func-
tional LXREs have been identified in the promoter region
of ChREBP, a glucose-activated transcription factor that
converts excess carbohydrates into lipids [20]. LXRs are
also implicated in regulating lipolysis within adipose tissue
[124]. In rodents, LXR agonism has been shown to reduce
adipocyte size [29], as well as increase serum levels of
glycerol and nonesterified free fatty acids, indicative of
increased triglyceride hydrolysis [111]. Altogether, dual
effects of LXRs on hepatic lipogenesis and adipocyte
lipolysis promote hyperlipidemia and insulin resistance,
which are undesirable phenomena in the development of
the metabolic syndrome.
The effect of LXRs on obesity has also been examined.
LXR null mice are resistant to diet-induced obesity and
exhibit significant reductions in adipocyte size [65, 74]. In
an alternative model of genetic obesity, LXRa/b-deficient
ob/ob mice remain obese and have increased adipose lipid
storage, but display reduced hepatic lipid accumulation and
improved insulin sensitivity compared to ob/ob mice [7].
Despite being more insulin sensitive, LXRa/b-deficient ob/
ob mice are, however, glucose intolerant and have impaired
pancreatic function. These data suggest that, although
LXRs may not protect against obesity, their expression
nevertheless influences lipid accumulation, insulin sensi-
tivity, and glucose homeostasis in the setting of obesity [7].
Other studies have shown that LXRs may affect obesity
through modulating pathways involved in nutrient status
and energy expenditure. LXR agonism downregulated
leptin expression in white adipose tissue in mice as well as
decreased UCP1 expression, leading to increased energy
intake and decreased energy expenditure, respectively
[125].
Alternatively, LXRs may protect against obesity through
anti-inflammatory functions that ameliorate the develop-
ment of insulin resistance. LXR agonism has been shown
to inhibit TNFa-stimulated release of inflammatory
cytokines in fat cells, while re-establishing insulin sensi-
tivity [41]. Thus overall, there is sufficient evidence to
suggest that LXRs modulate key components of the
metabolic syndrome.
LXR and chronic kidney disease
Nephropathy is a microvascular complication of diabetes
mellitus and uncontrolled hypertension, leading to chronic
kidney disease [112]. These, and other causes of chronic
kidney disease, are major contributors to cardiac damage
and are associated with an increased risk for cardiovascular
disease [13, 117].
LXRs have been implicated as a renoprotective target,
preserving intrinsic renal structure and function both
basally and in diabetic nephropathy. A homeostatic role for
LXRs in kidney function has been postulated. Lxrb-/-
mice exhibit polyuria and polydipsia, features of diabetes
insipidus [42], and mice deficient for both LXRs display a
renal phenotype analogous to diabetic nephropathy with
elevations in albumin:creatinine ratio and glomerular lipid
accumulation [99]. When challenged with diabetes, these
mice demonstrated accelerated mesangial matrix expan-
sion, increased glomerular lipid, and upregulation of
inflammatory and oxidative stress markers [99].
In the kidney, expression levels of both LXRs are sig-
nificantly decreased in animal models of type I diabetes
[105] and in patients with diabetic nephropathy [87].
Studies conducted in several diabetic rodent models
demonstrated that LXR activation with T09 and GW3965,
as well as a new generation agonist, N,N-dimethyl-3b-
hydroxycholenamide (DMHCA), prevented renal damage
and dysfunction by reducing urinary albumin excretion and
inhibiting macrophage infiltration, inflammation, and lipid
accumulation [72, 99, 126]. Besides local renal effects,
macrophage-derived LXR signaling is also pertinent in
renal pathophysiology as transgenic LXRa overexpression
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in macrophages protected from hyperlipidemic-hyper-
glycemic nephropathy [72]. These findings suggest that
LXRs play an important role in hyperglycemic-induced
kidney disease. Whether LXRs affect hypertension-asso-
ciated renal impairment remains to be established.
Local cardiac effects for LXRs
Relatively few studies have evaluated LXR signaling in the
heart itself. Both LXRa and LXRb are expressed in the
heart where in comparison to the cardiomyocyte fraction,
their expression levels are 10- to 15-fold higher in the non-
myocytic fraction consisting of fibroblasts and endothelial
cells [79]. In the heart, LXRs are induced and activated by
myocardial infarction [51, 79], chronic pressure overload
[17, 139], myocarditis [98], and diabetes [25, 52], indi-
cating that LXRs are regulated in cardiac (patho)physiol-
ogy. Here, we review current evidence regarding local
cardiac effects for LXRs and the potential role of LXR
signaling in the fundamental cellular processes governing
cardiac remodeling, including cardiomyocyte hypertrophy
and death, fibrosis, and metabolic and vascular remodeling
(Fig. 3).
Cardiomyocyte hypertrophy
Cardiomyocytes are non-proliferative, therefore they
respond to pathophysiological stimuli through hypertrophic
growth in order to reduce ventricular wall stress and aug-
ment contractile function. Increases in mechanical load as
well as various neurohumoral signals such as cate-
cholamines, growth factors, cytokines, and vasoactive
peptides, activate a cascade of signal transduction path-
ways within the myocyte that orchestrates transcriptional
reprogramming and posttranslational modification of pro-
tein synthesis and growth, as well as reactivation of fetal
contractile and metabolic gene expression (fetal gene
program). Initially, these adaptations are compensatory and
considered protective, but with unremitted stress, become
maladaptive and yield to pathological concentric or
eccentric growth.
Several lines of evidence suggest an important role for
LXRa in regulating hypertrophic cardiac remodeling. First,
Fig. 3 Cardiac effects of liver X receptor signaling. In the ischemic
or hypertrophic myocardium, LXRs decrease cardiomyocyte hyper-
trophy and loss (death), as well as attenuate fibrotic remodeling.
LXRs also modulate myocardial metabolism, and have regulatory
functions in angiogenesis and neovascularization. LXRs are also
expressed in macrophages, which can affect the myocardium through
injury or disease. NFjB, nuclear factor kappa B; VEGF, vascular
endothelial growth factor
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from in vitro experiments, LXR agonists have been shown
to decrease cellular hypertrophy induced by diverse
hypertrophic stimuli such as Ang II and lipopolysaccha-
rides [139], endothelin-1 [75], and phenylephrine [17],
whereas knockdown of LXRa in cardiomyocytes led to
increased cellular growth [17]. Second, LXRa protein
abundance is markedly upregulated in the pressure over-
loaded myocardium [17, 139]. Third, murine hearts defi-
cient for LXRa demonstrate an exacerbated hypertrophic
response to chronic pressure overload induced via trans-
verse aortic constriction (TAC) [139], whereas the LXR
agonists T09 and AZ876 attenuate hypertrophy in wild-
type mice [17, 75], but not in LXRa-null mice [75].
Finally, the effect of LXRa on cardiac hypertrophy is
heart-specific and independent of confounding systemic
effects attributed to either T09 activation, which are lipo-
genic [102], anti-inflammatory [142], and blood pressure-
lowering [75] effects, or residual effects from whole-body
LXRa deletion [73]. Cardiac-specific LXRa overexpres-
sion in transgenic mice protected the heart from TAC-in-
duced pressure overload and Ang II stimulation by
attenuating LV hypertrophy and preventing cardiac dys-
function, in both the early and later phases of LV remod-
eling [16]. Taken together, these findings suggest a cell-
specific role for LXRs in cardiomyocyte hypertrophy and
are supported by pharmacological and genetic studies.
The molecular basis for the antagonistic actions of
LXRa on pathological hypertrophic growth has been elu-
cidated. In cardiomyocytes, suppressed pro-inflammatory
NFjB signaling was found to be operative in T09-mediated
decreases in cellular growth [139]. There are, however,
various stages in the development of pathological cardiac
hypertrophy, and the induction of an inflammatory
response is only an early manifestation of this progression.
Further evidence indicates that, in the intermediate phase
of hypertrophy prior to decompensation and heart failure,
the cardioprotective effects of LXRa may involve tran-
scriptional regulation of myocardial glucose metabolism in
the adaptation to hypertrophic stress. Mice with cardiac
LXRa overexpression display an endogenous protective
phenotype evidenced by enhanced myocardial glucose
uptake that is linked to induction of potent anti-hyper-
trophic effectors, ANP and BNP. Specifically, increases in
glucose flux activate the hexosamine biosynthetic pathway,
which leads to downstream posttranslational O-GlcNAcy-
lation of transcription factors of natriuretic peptides,
GATA4 and Mef2c, potentiating their activities [16].
Cardiomyocyte death
Loss of cardiomyocytes is crucial in the pathogenesis of
myocardial infarction, ischemia/reperfusion (I/R), and
heart failure. Since cardiomyocytes are terminally
differentiated and generally incapable of replicating in the
adult heart, their survival is critical for maintaining
myocardial viability. Cell death arises when blood supply
to the myocardium is disrupted by coronary occlusion.
Ensuing hypoxic and ischemic stimuli increase ROS pro-
duction which triggers necrosis and apoptosis.
Recently, a role for LXR in apoptosis has been evalu-
ated in the infarcted heart. LXR agonist treatment
decreased infarct size and improved LV contractile func-
tion in murine hearts subjected to global I/R injury, and
prevented hypoxia-reoxygenation-induced apoptosis by
attenuating caspase 3 [79]. Furthermore, LXRa, but not
LXRb, was identified as the predominant isoform in the
protection against acute and chronic I/R injury, which was
associated with significant reductions in post-ischemic
myocardial apoptosis. These infarct-sparing effects occur-
red via inhibition of endoplasmic reticulum stress- and
mitochondria-mediated apoptotic pathways through tar-
geting of caspases 12 and 9, respectively [51]. In an
alternative therapeutic approach for cardiac repair follow-
ing myocardial infarction, the combined therapy of the
LXR agonist T09 and adipose-derived mesenchymal stem
cells (AD-MSCs) transplanted into infarcted hearts inhib-
ited host cardiomyocyte apoptosis and improved cardiac
function, while T09 further improved the survival of AD-
MSCs under hypoxic conditions [135]. Altogether, these
findings are consistent with other studies demonstrating
protective effects for LXRs in ischemic models of intesti-
nal and brain injury, although the mechanisms underpin-
ning LXR efficacy in these studies are linked to suppressed
pro-inflammatory NFjB signaling [23, 31, 118].
LXRs have also been shown to regulate cell survival
through inhibition of ROS production and oxidative stress
[47, 121], as well as prevent apoptosis induced by hyper-
glycemia [24] and diabetes [52]. Interestingly, the anti-
apoptotic factor AIM, also known as apoptosis inhibitor 6
or Spa, is a direct target gene for regulation by LXRa [62],
which serves to protect macrophages from the apoptotic
effects of oxidized lipids. Moreover, macrophages are
essential for wound healing following myocardial infarc-
tion as they are the primary initiators of phagocytosis of the
apoptotic cell. The inability to clear apoptotic cells is pro-
inflammatory, and LXR signaling has been demonstrated to
play an important role in apoptotic cell clearance and
enhanced macrophage phagocytosis [1, 107]. In summary,
LXRs may modulate critical facets of cellular death path-
ways in the ischemic and infarcted myocardium.
Fibrosis
Cardiac fibrosis is central in the pathogenesis of heart
failure and is a major constituent in LV remodeling
resulting from myocardial infarction and chronic pressure
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overload. With myocardial infarction, cardiomyocyte loss
is resolved by cardiac fibroblasts, which initiate wound
healing through replacement fibrosis to form a scar resilient
in preventing ventricular rupture. Fibrosis that develops
from pressure overload and in remote regions after
myocardial infarction is termed reactive fibrosis. This form
of fibrosis interferes not only with transduction of electrical
impulses and contractile force in myocytes, but impedes
diastolic relaxation through increased myocardial stiffness.
In response to pathological stimuli, fibroblasts proliferate
and differentiate into myofibroblasts, which contract and
secrete collagens. Increased collagen deposition as well as
changes in the balance of proteins regulating extracellular
matrix turnover disrupt normal matricellular architecture.
To date, there are no therapeutic strategies that specifically
target fibrogenesis in the heart.
LXR agonists exhibit anti-proliferative properties as
demonstrated in pancreatic b-cells [90], smooth muscle
cells [11, 37], lymphocytes [9], and cancer cells [28]. Both
LXRs are expressed in cardiac fibroblasts, and thus in the
heart, they may potentially reduce expansion of the
fibroblast population in LV remodeling. LXR activation
with the novel agonist AZ876 resulted in both suppressed
myofibroblast conversion and the prevention of Ang II- and
transforming growth factor b (TGFb)-induced collagen
synthesis [17]. Further, in murine models of chronic pres-
sure overload and diabetes, LXR agonism has been shown
to oppose increases in myocardial fibrosis and pro-fibrotic
gene expression in conjunction with improved diastolic
function [17, 52]. Cardiac-specific LXRa overexpression
also exerts anti-fibrotic effects and lowers fibrotic gene
expression [16]. These observations are in accordance with
other studies demonstrating anti-fibrotic effects of LXRs in
liver injury [8], diabetic nephropathy [72, 126], and
experimental skin fibrosis [10]. The latter two findings are
associated with the interference of LXR ligands in mac-
rophage infiltration and release of cytokines. Given that
multiple co-morbidities contribute to a sustained pro-in-
flammatory state particularly evident in HFpEF [136],
these effects on macrophage activity and fibrosis are of
clinical relevance. Also of note, LXRs have been reported
to downregulate matrix metallopeptidase MMP9 via
repressed NFjB signaling [19], suggesting a role for
macrophagic LXRs in regulation of extracellular matrix
turnover.
LXRs may counteract pro-fibrotic signaling in the heart
by affecting key intracellular pathways. For example, Ang
II signaling promotes fibroblast proliferation and extracel-
lular matrix formation through AT1 receptor-dependent
activation. Several studies have demonstrated downregu-
lation of AT1R by LXR agonism [57, 76, 80] through
dephosphorylation of the transcription factor, Sp1 [57].
TGFb is another central mediator of multiple inflammatory
and fibrotic cellular responses in cardiac remodeling [38].
A crosstalk between LXRs and TGFb signaling via inter-
action with the co-activator RAP250 and Smad2/3 has been
determined [3]. Furthermore, LXR agonism has been
shown to attenuate TGFb and downstream Smad2/3
expression in hypertrophied murine hearts [17], which is
consistent with their activation in other diseased states such
as diabetes-induced renal fibrosis [126] and chronic
asthma-induced airway remodeling [116]. These findings
altogether implicate a role for LXRs in fibrogenesis, raising
the possibility that they may serve as a protective target in
the prevention of fibrosis in cardiac remodeling.
Metabolic remodeling
The heart is a highly metabolic organ requiring continuous
replenishment of its cellular ATP stores to support sar-
comeric contraction and relaxation as well as functioning
of membrane transport systems. The demand for energy is
supplied primarily through oxidation of fatty acids, but also
glucose and to a lesser extent lactate, ketones, and amino
acids. However, pathological states trigger alterations in
myocardial substrate utilization in order to maximize
energy efficiency through reciprocal downregulation of
fatty acid oxidation and enhanced glucose reliance. As
heart failure progresses, myocardial metabolism in mal-
adaptive as oxygen and substrate supply are decreased and
energy transfer is impaired, resulting in mitochondrial
dysfunction and inefficient energy utilization. In essence,
the failing heart becomes ‘‘an engine out of fuel’’ [95] as
energy production is inadequate to support cardiac output.
Promoting the shift towards increased glucose reliance
has been postulated to improve myocardial efficiency in
heart failure, preventing energy depletion [5, 61]. LXRa
has been implicated in the transcriptional regulation of
cardiac glucose metabolism and orchestration of an adap-
tive metabolic response to hypertrophic stress. Constitutive
LXRa overexpression in isolated cardiomyocytes and
murine hearts induced Glut1 and Glut4 expression and
increased the capacity for glucose uptake and utilization.
Furthermore, mice deficient for LXRa display impaired
myocardial glucose uptake in response to hypertrophic
perturbation, whereas glucose levels are substantially
enhanced with cardiac LXRa overexpression in the pro-
tection against cardiac dysfunction [16]. Interestingly,
LXRa has also been shown to improve long-term cardiac
performance following chronic I/R injury that is evidenced
in part by preserved glucose uptake [51], an indicator of
myocardial viability in this setting. Whether preservation
of glucose uptake was a direct effect of LXRa on glucose
metabolism, or secondary to reduced infarct size was not
established herein. In contrast, lipid droplet accumulation
has been observed following treatment with the LXR
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agonist GW3965, which associated with improved toler-
ance to acute myocardial ischemia [79]. At the onset of I/R
there is increased availability and usage of fatty acids [66].
However, the role of lipids in the heart remains contro-
versial as it may lead to lipotoxicity and dysfunction [97].
Glucose pathways were not assessed in this study and
therefore cannot be precluded as a protective mechanism
against acute myocardial infarction.
Targeting LXRa to promote cellular glucose uptake may
indeed be advantageous under conditions where glucose
uptake is compromised. For example, insulin resistance is
highly prevalent in the diabetic and heart failure population
and can impair the shift to glucose reliance [13, 93, 138].
LXRa may therefore serve as an important tool in sensi-
tizing the heart to glucose under these conditions. Recently,
LXR agonism has been shown to protect against diabetic
cardiomyopathy in db/db mice, although the effects on
cardiac metabolism were not investigated in this study [52].
An alternative investigation in mice overexpressing cardiac
LXRa revealed that the elevated capacity for myocardial
glucose uptake is sustained despite obesity-induced sys-
temic insulin resistance and hypertriglyceridemia (Cannon
et al., unpublished data), stimuli that impede the capacity
for glucose uptake. Overall, LXRs represent a potential
metabolic modulator for optimization of myocardial sub-
strate utilization in cardiac pathophysiology.
Angiogenesis
Endothelial dysfunction involves a range of endothelial cell
functions that become dysregulated, including impaired
angiogenic responses that are crucial in salvaging the
infarcted and hypertrophic myocardium [35]. In HFrEF,
new microvascular networks are necessary for improving
regional perfusion after ischemic injury. In HFpEF, mus-
cle-to-capillary ratio is reduced in pathologically hyper-
trophied hearts, which causes myocardial hypoxia and
contractile dysfunction through compromised oxygen and
nutrient delivery that is necessary for growth. The aim of
cardiovascular therapies is to stimulate angiogenesis within
the myocardium to prevent or reverse heart failure.
The angiogenic potential of LXRs has been established
in the ischemic rat brain [118] and following stroke [21].
LXRs promote angiogenesis by directly regulating VEGF
[134]. Murine and human Vegfa genes harbor a functional
LXRE in the promoter region, and regulation occurs
independent of the hypoxia response element for HIF-1
[134]. However, several studies provide evidence for an
anti-angiogenic (yet protective) role for LXRs in settings of
uncontrolled angiogenesis such as in tumor growth [96]
and cancer [36, 104]. Whether LXRs stimulate angiogen-
esis in either the ischemic or hypertrophic myocardium
remains to be determined.
LXRs may also regulate angiogenesis through modula-
tion of cholesterol. Cholesterol promotes lipid raft forma-
tion in the plasma membrane from where cell surface
receptors initiate signaling events that lead to angiogenesis
[40]. Since excess cholesterol or its removal determines the
balance between either promoting or inhibiting angiogen-
esis, this balance may arguably be regulated by LXRs
given their antagonistic actions on increasing HDL
cholesterol [113] and stimulating cholesterol efflux via the
RCT [94]. These data implicate a role for LXR in angio-
genesis and suggest that LXRs may prevent tissue hypoxia,
either through directly targeting VEGF or through modu-
lation of cholesterol.
Conclusions
Heart failure is a complex clinical syndrome, and co-
morbidities such as hypertension, diabetes, and kidney and
vascular disease, including atherosclerosis, are increasingly
recognized for their provocation of this disease. Left
untreated, these co-morbidities accelerate the progression
of adverse myocardial remodeling which results in
impaired cardiac function, eventually leading to heart
failure and death. The optimal window for therapeutic
modulation likely occurs in the early phase when cardiac
remodeling is largely reversible. Since systemic LXR
activation may exert many roles in the pathogenesis of the
aforementioned co-morbidities, targeting of LXRs during
this phase may serve as a useful addendum in preventing
remodeling progression. In addition, accumulating evi-
dence implicates intracardiac LXR signaling in the pro-
tection against pathological processes involving myocyte
hypertrophy and loss, fibrosis, and metabolism. However,
translation of basic findings to clinical settings requires
additional studies to further elucidate the role of LXRs in
the heart. In the presence of multiple co-morbidities, the
collective impact of systemic LXR activation on preserving
myocardial integrity and function warrants further address.
Thus far, only few data exist on the role of LXR sig-
naling in humans. In a human genetic study, analysis of the
LXR gene sequence in patients afflicted with coronary
artery disease revealed mutations in the ligand-binding
domain of LXRa that altered its conformation, rendering
LXRa inept in binding its ligands [34]. This suggests that
humans having a mutated LXRa gene may develop a
predisposition towards coronary artery disease. In further
support of this, an LXRa gene polymorphism was found to
be related with increased susceptibility of coronary artery
disease in Chinese Han population [144]. Genetic variation
in the LXRa-encoding gene NR1H3 has been associated
with increased risk of ischemic vascular disease [123], as
well as LV hypertrophy (Van der Harst et al., unpublished
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data), obesity [32, 110], longevity [91], and the metabolic
syndrome [78], although another study was not able to
validate the latter [110]. Polymorphisms in the NR1H2
gene encoding LXRb mainly associated with obesity and
type 2 diabetes [32, 70, 119]. Interestingly, the LXR sig-
naling pathway was recently found to be highly enriched
among pleiotropic genes that emerged from cardiovascular
disease risk factor clustering, and for coronary artery dis-
ease [106], supporting the notion that the LXR pathway
may affect many cardiometabolic traits.
Future perspectives
Testing of high affinity agonists specific for LXRs are
needed to further evaluate the potential of LXR activation
in human disease, and provide more appreciable insight
into their therapeutic prospective [55]. To date, only one
clinical study has been published for the LXR agonist,
LXR-623, which activated LXRs without causing hepatic
lipogenesis. However, this clinical trial was prematurely
halted due to adverse neurological side effects in subjects
tested [69]. Nevertheless, several other LXR agonists are in
development and natural modulators of LXR activity are
also being considered for their potential as nutraceuticals
for therapy [56]. Recently, a novel partial, LXRb-selective
agonist, BMS-779788, has been shown to display an
improved plasma lipid profile compared with a dual agonist
in a cynomolgus monkey model, while inducing genes that
enhance the RCT [71]. Indeed, much of the current interest
in developing new generation compounds is channeled
towards designing LXRb-specific ligands that target
induction of the RCT pathway and circumvent the hepatic
lipogenic signaling pathways mediated by LXRa. How-
ever, in the heart, there is mounting evidence to suggest
that LXRa is the predominant isoform in the protection
against distinct myocardial pathologies related to ischemia
[51], pathological hypertrophy [16, 17, 139], and diabetic
cardiomyopathy [25]. Ideally, a tissue-selective LXR ago-
nist with high affinities for cardiac LXRa may be more
suitable for treating myocardial disease. A strategy to
exclusively target LXRa pathways in a given cell, or tissue,
such as in the heart, is to modulate the LXR co-regulatory
transcriptional complex, which impacts its DNA-binding
and transcriptional activity [2, 53, 132]. Hence, a greater
understanding of the co-factor profile recruited to regulate
LXRa in the normal and diseased heart may aid in this
development.
In perspective, bridging the gap between preclinical
studies and a clinically viable therapeutic strategy most
likely lies in the development of highly specific and
selective LXR ligands that minimize lipogenic and
neurological side effects, and are well tolerated in
clinical trials. Given the global salutary effects of LXR
activation in cardiovascular disease and its precursors,
atherosclerosis, hypertension, diabetes, and inflamma-
tion, we postulate that effective and successful target-
ing of LXRs holds promise for future therapies.
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